Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Cancer Immunol Immunother. 2011 Dec 24;61(7):1125–1136. doi: 10.1007/s00262-011-1187-z

Fig. 4.

Fig. 4

Quality of PR1-specific CD8+ T-cell response and GVL. a Avidity of PR1-specific CD8+ T cells was compared for patients with CML and ALL. Stimulation of PBMC with 0.1 and 10 μM of PR1 determined high- and low-avidity responses. Results show ratios of high- to low-avidity PR1 CD8+ T-cell responses in CML and ALL patients. Ratios were obtained by the following calculation: IFN-γ+ CD8+ T-cell (%) with 0.1 μM peptide/IFN-γ+ CD8+ T-cell (%) with 10 μM peptide. A ratio >1.0 represents predominantly high-avidity responses, whereas a ratio of <1.0 represents predominantly low-avidity responses. b Relationship between IFN-γ+ PR1-specific CD8+ T-cell responses and MRD at day +180 post-SCT, as assessed by BCR-ABL expression in CML and WT1 expression in ALL. Bars represent median values